Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02754596 | Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution | PHASE2 | COMPLETED | 154 | — | — | Mar 29, 2016 | Jul 21, 2020 | Sep 26, 2023 | 1 | United States |
Change from baseline in IOP (measured in mmHg) at week 12. Negative values represent reductions in IOP from baseline.
| Arm | Type | Description |
|---|---|---|
| Travoprost Intraocular Implant, high elution | EXPERIMENTAL | This implant will be surgically implanted and elute travoprost, a prostaglandin. |
| Travoprost Intraocular Implant, low elution | EXPERIMENTAL | This implant will be surgically implanted and elute travoprost, a prostaglandin. |
| Timolol Maleate Ophthalmic Solution, 0.5% | ACTIVE_COMPARATOR | Timolol, a beta blocker, will be dosed twice daily |
| Name | Type | Description |
|---|---|---|
| Travoprost Intraocular Implant, high elution | DRUG | Surgical implant placed within the eye to elute travoprost. |
| Travoprost Intraocular Implant, low elution | DRUG | Surgical implant placed within the eye to elute travoprost |
| Timolol Maleate Ophthalmic Solution, 0.5% | DRUG | Instillation of one drop of timolol in the study eye twice daily |
Inclusion Criteria: * Open angle glaucoma Exclusion Criteria: * Uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular disorders. * Functionally significant visual field loss, including severe nerve fiber bundle defects. * Prior glaucoma surgery. * Uncontrolled syst...